Alkermes Sees Payer Savings Opportunity With Aristada Approval
This article was originally published in The Pink Sheet Daily
Long-acting injectable aripiprazole lauroxil cleared six weeks late, but Alkermes is happy with label's flexibility on dosing, saying product will be differentiated from Abilify Maintena.
You may also be interested in...
The CNS specialist outlined long-term commercial prospects for four drugs in its “emerging blockbuster” portfolio during an investor day presentation. The company also unveiled a new clinical candidate, a drug for the treatment of Alzheimer’s agitation.
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.
The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Reduction Act program with Novo’s recent complaint, which objects to the aggregation of its insulin products.